ArticleCancer medicine2025
Overall and Site-Specific Cancer Mortality Among Older Migrants and Nonmigrants in Finland: A Population Register Study on All Deaths, 2002-2020.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveThis study examined all-cause and cause-specific cancer mortality among older migrants and non-migrants in Finland and the role of socioeconomic status in mortality differences.
methodsWe used the Finnish Causes of Death Register on all deaths (2002-2020) among individuals aged ≥ 70 (N = 718,717) and the corresponding population-at-risk data (N = 13,241,620 person years). Poisson regression was used with two sequential models adjusting for age at death, calendar year, and region of residence in Finland (M1), and personal annual disposable income (M2).
resultsWe found an overall cancer mortality advantage for both migrant men (IRR in the full model 0.83, 95% CI: 0.78-0.89) and migrant women (IRR: 0.89, 95% CI: 0.83-0.95) and lung cancer mortality advantage for migrant men (IRR: 0.77, 95% CI: 0.67-0.89) and women (IRR: 0.67, 95% CI: 0.53-0.85). For migrant men, advantage was found in pancreatic cancer (IRR: 0.76, 95% CI: 0.58-0.99), prostate cancer (IRR: 0.78, 95% CI: 0.66-0.93), and leukaemia and lymphoma (IRR: 0.73, 95% CI: 0.58-0.93), and for women in genital cancers (IRR: 0.69, 95% CI: 0.55-0.86). Notable variations were observed by region of origin and in certain cases, migrants' lower income obscured the full extent of their cancer mortality advantage. A mortality disadvantage was observed in stomach cancer among men (IRR: 2.76, 95% CI: 2.08-3.65) and women (IRR: 2.32, 95% CI: 1.79-3.00) born in the former USSR. Liver cancer mortality disadvantage was found for men from the Global South and East (IRR: 2.00, 95% CI: 1.10-3.61), and this association was attenuated after adjustment for personal disposable income. In cancers of the urinary tract, men born in Sweden had elevated mortality (IRR: 2.09, 95% CI: 1.14-3.81).
conclusionFinings underscore the need for targeted cancer prevention and screening programmes that account for the diverse backgrounds, sex, socioeconomic status, and health risks of migrant populations, particularly those from higher-risk regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.